MartinLutherKing
12時間前
There are over 100 studies of the role of miR-10b in at least 18 cancer types over the last 15 years, including some with contributions from our co-founders, making it one of the most studied microRNAs. Studies have shown that an inhibition of miR-10b "prevents the onset of metastasis and eliminate existing metastases, even after treatment has been discontinued." Metastases are responsible for about 90% of all cancer deaths, due to a lack of therapeutics. In Phase 0, a microdose of TTX-MC138 reduced miR-10b by 66%, 24 hours after injection. In another study, MN-anti-miR10b decreased miR-10b by 90% in 24-48 hours, and a 99% downregulation was observed within two weeks. It seems as though this data is quick to ascertain. It's been over two months since the first Phase 1 patients were dosed with 0.4mg/kg of TTX-MC138.
How can the CEO say there can be no assurance that this data will be released?
georgie18
22時間前
Did a search on XCUR and your RNAZ post came up...🥳...Don't know if you are aware...
BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company:
Dear Shareholders,
At our upcoming Special Meeting to be held November 22, shareholders are being asked to authorize our Board of Directors to effect a reverse split — only if the Board determines that doing so is necessary as described below.
Many shareholders rightly ask why this request. Some believe that the potential announcement of additional positive clinical data or other good news will favorably impact our stock price. However, there is no assurance that any good news will occur, will occur by the deadline required, or that the stock will rise after any such positive announcement(s).
A reverse split is NOT something directors or management wishes to do — we all hope it won’t be needed. But the Nasdaq Hearings Panel that approved the extension to continue our Nasdaq listing did so on the condition that our shareholders authorize a reverse split — should one be necessary. The reverse split will not be necessary if our stock closes at $1.00 per share or more for any ten-day period prior to December 31, 2024.
If our stock does not meet this Nasdaq requirement, and we do not have your vote in favor of the reverse split, Nasdaq will delist our stock. A Nasdaq delisting would in all likelihood have a material adverse effect on the value of our company and the value of your stock.
Our assessment boils down to this: your vote is your decision about whether you support our efforts to maintain our Nasdaq listing. Given our need to raise additional capital as soon as possible to continue the clinical trial and other operations, we believe having our stock remain on Nasdaq is critical to raising the needed capital.
TransCode’s management and directors are unanimously determined to maintain our Nasdaq listing. This is why we need you to authorize the reverse split, with all of us hoping that we will not have to implement this decision.
We call for your understanding and greatly appreciate your support.
MartinLutherKing
6日前
H.C. Wainwright & Co. reiterates RNAZ as a Buy, and maintains its $3 PT.
3) A RS "will not be necessary if our stock closes at $1.00 per share or more for any ten-day period prior to December 31, 2024."
4) There are 11.24M warrants at $1.22, for a total of $13.7M in funding, and another 357K at $1.525 for $543.7K.
5) On Jan. 18, 2025, another batch of 500K warrants at $0.375 become exercisable for $187.5K in funding.
MartinLutherKing
6日前
The "doctors" at RNAZ, along with their partners/MMs/friends/family, can turn this thing around without a ratification/RS/offering, or they can face delisting, bankruptcy or a buyout. If I were Tom, I'd be on the phone nonstop, or does he not know anyone who believes in them?